MARGARET CUSACK: Open Payments
NPI 1902929987 · COPPELL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,239 in 69 payments from 21 companies in 2025. Trend: 2023 $656 · 2024 $1,235 · 2025 $1,239
Food & beverage: $1,239
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $227 |
| ABBVIE INC. | 10 | $137 |
| Otsuka America Pharmaceutical, Inc. | 6 | $104 |
| Gilead Sciences, Inc. | 3 | $77 |
| Axsome Therapeutics, Inc. | 5 | $75 |
| Novo Nordisk Inc | 4 | $70 |
| PFIZER INC. | 3 | $62 |
| Dexcom, Inc. | 2 | $50 |
| Indivior Inc. | 3 | $50 |
| Abbott Laboratories | 2 | $48 |
Products named: CAPLYTA, REXULTI, Auvelity, Wegovy, UBRELVY, Dexcom G6 Transmitter, SUBLOCADE, VRAYLAR.
Industry payments across TX — which companies pay providers there.
